---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-004517"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2025-01-17T23:59:59+00:00"
generated_at: "2026-05-27T23:03:39.692360+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nasdaq bid price compliance regained; equity compliance deadline extended to May 19

## Summary
- Cara regained Nasdaq minimum bid price compliance after 1-for-12 reverse stock split effective Dec 30; letter received Jan 16.
- Stockholders' equity of $707k at Sep 30 below $2.5M minimum; extension granted to May 19, 2025.
- Extension conditional on closing proposed merger with Tvardi, which is expected to meet initial listing criteria.
- Company must also satisfy all applicable Nasdaq initial listing standards at merger close.

## SEC filing metadata
- accession: 0001104659-25-004517
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2025-01-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465925004517/0001104659-25-004517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465925004517/tm2430195d6_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-004517
- JSON: https://secwatch.observer/filing/0001104659-25-004517.json
- Plain text: https://secwatch.observer/filing/0001104659-25-004517.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.